Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 1:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Peanut Allergy
Interventions: VLP Peanut, Placebo; Biological
Lead sponsor: Allergy Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 10
States / cities: Tucson, Arizona • Tampa, Florida • Kansas City, Kansas + 7 more

Conditions: Myopia, Progressive
Interventions: OT-101 Ophthalmic Solution, Vehicle; Drug
Lead sponsor: Ocumension (Hong Kong) Limited; Other
Eligibility: 3 Years to 15 Years
Enrollment: 678 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 15
States / cities: Colorado Springs, Colorado • Fort Collins, Colorado • Gainesville, Florida + 12 more

Conditions: Actinic Keratosis
Interventions: Ingenol mebutate gel, placebo; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Carmel, Indiana

Conditions: Non-alcoholic Steatohepatitis
Interventions: MGL-3196, Placebo; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 26
States / cities: Dothan, Alabama • Tucson, Arizona • Coronado, California + 23 more

Conditions: Cognitive Impairment
Interventions: Phenytoin 200 mg capsule, Megestrol 800 mg liquid, Phenytoin-matched Placebo capsule, Megestrol-matched liquid Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pain
Interventions: Fentanyl, oxycodone/acetaminophen; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Pain, Postoperative
Interventions: Liposomal bupivacaine, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rheumatoid Arthritis
Interventions: Fostamatinib, Adalimumab, Placebo of Fostamatinib, Placebo of Adalimumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 6
States / cities: Glendale, Arizona • Paradise Valley, Arizona • Phoenix, Arizona + 3 more

Conditions: Behavioral Pharmacology of Cannabis
Interventions: cannabis; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Aging
Interventions: Beetroot Juice, Placebo Beetroot Juice; Dietary Supplement · Other
Lead sponsor: Marquette University; Other
Eligibility: 60 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Scar Prevention
Interventions: EXC 001, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Chicago, Illinois • St Louis, Missouri

Conditions: Dyskinesia, Cerebral Palsy
Interventions: Placebo, Valbenazine; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 6 Years to 70 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 19
States / cities: San Diego, California • Aurora, Colorado • Stamford, Connecticut + 16 more

Conditions: Bipolar Disorder With Manic or Mixed Episodes
Interventions: MEM 1003; Drug
Lead sponsor: Memory Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 21
States / cities: Little Rock, Arkansas • Garden Grove, California • Riverside, California + 15 more

Conditions: Sedation
Interventions: Dexmedetomidine load, Ketamine load, Midazolam load, Fentanyl load, Dexmedetomidine maintenance, Ketamine maintenance, Midazolam demand, Fentanyl demand, Benadryl demand; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Refractory Partial Seizures
Interventions: E2007 (perampanel), Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 32
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more

Conditions: Scalp Psoriasis
Interventions: Calcipotriene/Betamethasone Dipropionate, Taclonex®, Placebo; Drug
Lead sponsor: Glenmark Pharmaceuticals Ltd. India; Industry
Eligibility: 18 Years and older
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 31
States / cities: Encinitas, California • Fremont, California • San Diego, California + 25 more

Conditions: Seborrheic Keratosis (SK)
Interventions: A-101 25%, A-101 32.5%, A-101 40%, A-101 Vehicle; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Pain, Neuropathic Pain, Nociceptive Pain
Interventions: Relief Active Study Product 1.1 Usage, Relief Active Study Product 1.2 Usage, Placebo Control Form 1, Relief Active Study Product 2.1 Usage, Placebo Control Form 2, Placebo Control Form 3, Relief Active Study Product 3.1 Usage, Relief Active Study Product 3.2 Usage, Relief Active Study Product 3.3 Usage; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years to 105 Years
Enrollment: 2,016 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis, Pneumocystis, Mold Infection, Invasive Fungal Disease, Prophylaxis of Invasive Fungal Infections, Aspergillus
Interventions: Rezafungin for Injection, Posaconazole, Fluconazole, Trimethoprim-sulfamethoxazole (TMP/SMX), Intravenous Placebo, Oral Placebo; Drug
Lead sponsor: Mundipharma Research Limited; Industry
Eligibility: 18 Years and older
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 13 more

Conditions: Insulin Sensitivity
Interventions: Sevelamer, Synbiotic, Maltodextrin, High Fat diet, Low Fat diet; Drug · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Breast Cancer
Interventions: Entinostat, Atezolizumab, Placebo; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 19
States / cities: Birmingham, Alabama • Bakersfield, California • Fullerton, California + 15 more

Conditions: Healthy Volunteers
Interventions: LY3023703, Placebo, Celecoxib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Gastrointestinal Cancer, Gastrointestinal Neoplasms, Chemotherapy-Induced Thrombocytopenia
Interventions: Avatrombopag, Matching Placebo; Drug
Lead sponsor: Hanny Al-Samkari, MD; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 4
States / cities: Miami, Florida • Boston, Massachusetts • Portland, Oregon + 1 more

Conditions: Hidradenitis Suppurativa
Interventions: Bimekizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more

Search by objective public record fields.

Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects

Study of OT-101 in Treating Myopia

Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis

Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)

Phenytoin for Memory Impairment Secondary to Megestrol

Safety and Efficacy Study of Fentanyl Buccal Tablet Use in the Emergency Department for Isolated Extremity Injury

Liposomal Bupivacaine at Cesarean Delivery to Decrease Post-operative Pain

Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study

Differences in Cannabis Impairment and Its Measurement Due to Route of Administration

Exercise Fatiguability in Older Adults: The Protective Effects of Dietary Nitrate Supplementation

Safety and Efficacy Study of Different Dose Levels of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty

Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy

Safety and Efficacy of MEM 1003 Versus Placebo for the Treatment of Patients With Bipolar I Disorder

Alternative Sedation During Bronchoscopy

To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis

Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis

Radicle Relief 2: A Study of Health and Wellness Products on Pain and Health Outcomes

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim 1)

Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In

A Single Dose Study of LY3023703 in Healthy Participants

Avatrombopag vs. Placebo for CIT in GI Malignancies

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa